Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying he believes the stock's upside drivers are more limited over the next year. 2. Rite Aid (RAD) downgraded to Neutral from Buy at Mizuho. 3. Fairmount Santrol (FMSA) was downgraded to Sell from Neutral at Goldman Sachs and to Neutral from Outperform at Credit Suisse. 4. New Relic (NEWR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Sanjit Singh saying shares are up 71% year-to-date and valuation captures solid fundamentals but sees fewer catalysts. 5. Smart Sand (SND) downgraded to Neutral from Outperform at Credit Suisse with analyst James Wicklund saying the regional sand volumes capacity is expanding much faster than had been expected. This drives lower pricing and demand for non-Texas mines, he adds. The analyst also lowered his price target on the shares to $8.50 from $20. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.